Treatment-free remission in non-transplanted Ph+ #ALL pts is feasible in carefully selected pts. Those in CR1 (n=6) who maintained CMR for >48 mos did not relapse following TKI discontinuation. @mdanderson.bsky.social doi.org/10.1002/cncr... @nitinjainmd.bsky.social @niranjankhaire.bsky.social

In an interview from #ASH24, @nitinjainmd.bsky.social of @mdanderson.bsky.social discusses an analysis assessing the safety of discontinuing TKIs in patients with Ph+ ALL not undergoing alloSCT. Click here to watch: 👉 https://buff.ly/4hqSeue 👈 #ALLsm #Leusm #Leukemia #HemOnc

As we have increasing Rx options in Firstline #CLL including new updates from #ASH24, here is a summary slide I made for PFS in selected trials by IGHV status caveat: cross trial comparison but still helpful as we look across trials #CLL #leusm @MDAndersonNews @ASH_hematology

Great fun last night at Bollywood themed ASH President’s reception

Ready to get things started at #ASH24! @nitinjainmd.bsky.social

👉👉👉 #ASH24 TFR (Treatment free remission) is a well established concept in CP CML. But can you do TFR in Ph+ ALL in CR1 among pts who don’t undergo allo-SCT? 👉14 pt retrospective series at #ASH24 Please see us at the poster on Saturday in San Diego. Work led by Drs Kugler and Khaire

Stargazing in Joshua Tree National Park on Thanksgiving night

How was your weekend??!!